Conformational lability in the class II MHC 3-10 helix and adjacent extended strand dictate HLA-DM susceptibility and peptide exchange by Painter, Corrie A. et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
GSBS Student Publications Graduate School of Biomedical Sciences 
2011-11-29 
Conformational lability in the class II MHC 3-10 helix and adjacent 
extended strand dictate HLA-DM susceptibility and peptide 
exchange 
Corrie A. Painter 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/gsbs_sp 
 Part of the Biochemistry, Biophysics, and Structural Biology Commons, Chemistry Commons, and the 
Medicine and Health Sciences Commons 
Repository Citation 
Painter CA, Negroni MP, Kellersberger KA, Zavala-Ruiz Z, Evans JE, Stern LJ. (2011). Conformational 
lability in the class II MHC 3-10 helix and adjacent extended strand dictate HLA-DM susceptibility and 
peptide exchange. GSBS Student Publications. https://doi.org/10.1073/pnas.1108074108. Retrieved from 
https://escholarship.umassmed.edu/gsbs_sp/1762 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in GSBS Student 
Publications by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
Conformational lability in the class II MHC 310 helix
and adjacent extended strand dictate HLA-DM
susceptibility and peptide exchange
Corrie A. Paintera, Maria P. Negronib, Katherine A. Kellersbergerc, Zarixia Zavala-Ruizd, James E. Evansa,
and Lawrence J. Sterna,b,1
Departments of aBiochemistry and Molecular Pharmacology and bPathology, University of Massachusetts Medical School, Worcester, MA 10655; cBruker
Daltonics, Billerica, MA 01821; and dDepartment of Chemistry, University of Puerto Rico, Rio Piedras, San Juan, Puerto Rico 00931
Edited by Peter Cresswell, Yale University School of Medicine, New Haven, CT, and approved October 17, 2011 (received for review May 19, 2011)
HLA-DM is required for efﬁcient peptide exchange on class II MHC
molecules, but its mechanism of action is controversial. We trapped
an intermediate state of class II MHC HLA-DR1 by substitution of
αF54, resulting in a protein with increased HLA-DM binding afﬁnity,
weakened MHC-peptide hydrogen bonding as measured by hydro-
gen-deuterium exchange mass spectrometry, and increased suscep-
tibility to DM-mediated peptide exchange. Structural analysis
revealed a set of concerted conformational alterations at the N-ter-
minal end of the peptide-binding site. These results suggest that
interaction with HLA-DM is driven by a conformational change of
the MHC II protein in the region of the α-subunit 310 helix and ad-
jacent extended strand region, and provide a model for the mecha-
nism of DM-mediated peptide exchange.
antigen presentation | antigen processing | major histocompatibility
proteins | chaperone | protein folding
HLA-DM (DM) facilitates peptide exchange on class II MHC(MHC II) proteins, and is required for efﬁcient peptide
loading in vivo (1). MHC II molecules assemble in the endoplas-
mic reticulum with the class II-associated invariant chain chaper-
one, which is subsequently cleaved by endosomal proteases leaving
a short fragment known as CLIP bound in the MHC peptide-
binding groove (2). DM facilitates the exchange of CLIP for
peptides generated by digestion of endogenous and exogenous
proteins, resulting in a library of peptide antigens bound to MHC
II proteins that are transported to the cell surface (3, 4). In vitro
experiments have corroborated the roles for DM as a peptide-
exchange factor (5, 6) and as a molecular chaperone that prevents
peptide-free MHC II molecules from becoming inactive and from
forming aggregates (7, 8).
The mechanism by which DM mediates these effects has re-
ceived much attention (7–17). Peptides are released by DM with
different rates (18), with DM susceptibility a major factor in
whether or not a particular peptide is recognized by the cellular
immune system (19–21). Understanding the mechanism of DM-
mediated peptide release would promote efforts to predict im-
munogenicity of known and emerging pathogens. Moreover, the
mechanism involves catalysis of a protein conformational change
(16), and its elucidation would have implications for our un-
derstanding of protein-folding processes. However, despite in-
tensive investigation and crystal structures of both MHC II and
DM proteins, the mechanism of DM-facilitated MHC-peptide
binding and exchange is not understood. Part of the difﬁculty in
developing an understanding of the interaction of DM and MHC
II may be because of the presence of multiple conformers of DM
(22), as well as MHC II (10, 23). Previous studies using directed
screens (11, 14) and tethering approaches (24, 25) have identiﬁed
residues from both DM and MHC II that are critical for the
functional interaction. These residues include a cluster of acidic
residues on DM (14) and several residues in the vicinity of the P1
pocket of MHC II (9, 11, 15). Models for the DM–MHC II
complex that place these regions in apposition have been proposed
(11, 26). However, structural characterization of the DM–MHC II
complex, dynamic changes that occur as a result of the interaction,
and how formation of the complex facilitates peptide exchange
have not been described.
In part because of the paucity of structural information, models
for the interaction of DM with MHC II have been controversial.
Disruption of the MHC-peptide H-bond network was put forth as
an attractive target for DM because it allows for a peptide se-
quence-independent exchange mechanism (6). In this type of
model, DM-induced disruption of one or more of the ∼16 con-
served H-bonds between the peptide backbone and conserved
MHC II main-chain and side-chain atoms results in catalyzed
peptide exchange (13, 15). However, mutagenesis of the MHC II
side chains involved in these interactions have shown for the most
part that disruption of individual H-bonds does not diminish DM
catalysis (15). Other models include roles for conformational het-
erogeneity and involvement of peptide side-chain interactions. One
study suggests that DM recognizes a ﬂexible conformation of MHC
II with alterations of the P1 pocket (10), and another recent study
has suggested that spontaneous release of the peptide from the P1
pocket is prerequisite to DM interaction (9). In contrast, a study of
many MHC II and peptide variants suggests that interactions along
the entire peptide-binding groove contribute to the susceptibility of
DM (18), and it has also been suggested that DM functions by re-
ducing the cooperativity of peptide side-chain interactions and
mediating peptide exchange by way of a “push-off”mechanism (27).
In this work, we used a newly developed mass spectrometry
(MS) approach to establish the relative strength of the individual
H-bonds along the backbone of MHC II-bound peptide. Through
targeted mutagenesis of MHC II residues in the vicinity of the
peptide N terminus and P1 pocket, we identiﬁed a point sub-
stitution that results in alterations within the H-bonding network,
increased susceptibility to DM-mediated peptide exchange, and
greatly increased DM binding afﬁnity. Structural characterization
of the protein revealed an altered MHC II conformation in
a molecule contacted at the presumptive DM interaction site, with
alterations in the α-subunit 310 helical region (α45–50) and
ﬂanking extended strand region (α51–54). These changes appear
to be key structural determinants for DM interaction and
peptide exchange.
Results
Measurement of MHC-Peptide H-Bond Strengths Using Hydrogen-
Deuterium Exchange MS. The MHC II-peptide H-bonds are be-
lieved to be of fundamental importance to the MHC II-peptide
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interaction, but their role in DM-mediated catalysis has been
controversial (12, 13, 17, 18), in part because of a lack of methods
to examine the strength of these bonds directly. We devised an
experimental protocol that uses amide hydrogen-deuterium ex-
change (HDx) and MS to examine the strengths of the MHC II-
peptide H-bonds in native, unlabeled MHC II-peptide complexes.
Amide hydrogens exchange with solvent on a time scale of milli-
seconds to hours, with the exchange rate depending on the
strength of the amide H-bond (28). As outlined in Fig. 1A, we
stripped the peptide from the MHC II under conditions that
preserve the pattern of amide H/D present in the MHC-peptide
complex, and used high-resolution linear trap quadrupole HPLC/
MS to evaluate HDx in MHC II-peptide amide bonds by direct
examination of the released peptide.
For the free HA peptide in H2O solution, the average mass
(1,503.8) and the stable isotope ion distribution pattern (Fig. 1B,
Left) correspond with that expected for the HA peptide sequence
and the known isotope abundances. For the free HA peptide
transferred to 90% D2O solution, the average mass increases to
1,511.9, with changes in the mass spectrum (Fig. 1B, Center),
corresponding to addition of 12 D, after accounting for back-ex-
change during the analysis (SI Appendix, Fig. S1), as expected for
the 12 amide bonds in the HA peptide. For the MHC II-HA
complex immediately after transfer to 90%D2O, the average mass
is 1,504.6 (Fig. 1B, Right). Thus, interaction with the MHC II
protein protects ∼90% of the peptide amides from exchange.
With increasing time in D2O, additional H/D exchange is ob-
served, with multiphasic kinetics (Fig. 1C, black line). The time-
dependent H/D exchange kinetic is ﬁt well by an exponential
equation that describes an unresolved initial phase (t1/2 < 1 min),
a fast phase with half-time of a few minutes, and a much longer
slow phase with a half-time of ∼18 h (SI Appendix, Table S1). The
slow phase is still substantially faster than the rate of peptide re-
lease (Fig. 1D). Overall, this analysis reveals that the bound pep-
tide’s amide NH bonds exchange at dramatically different rates.
We were able to assign several individual peptide amides to
particular kinetic phases using multidimensional electron transfer
dissociation (ETD) MS (29). In ETD, peptides are fragmented
between NH and Cα atoms (Fig. 2A), producing sets of c-series
and z-series ions (Fig. 2B), analogous to the b-series and y-series of
conventional collision-induced dissociation (29). Unlike collision-
induced dissociation, however, ETD does not result in H/D
scrambling (30), so that the ion fragments retain the pattern of
deuterium incorporation present in the eluted peptides. Peptide
fragments exhibit different kinetics of deuterium incorporation,
depending on the protection of the particular amide NH atoms
present in that fragment. For example, the c3 fragment has very
little deuterium incorporation, even at 512 min, whereas the c6
fragment is substantially exchanged by 2 min (Fig. 2C). We were
able to measure deuterium incorporation rates for six c-series ions
(c2, c3, c5, c6, c8, and c9) and seven z-series ions (z4, z5, z7, z9, z10,
z11, and z12), although with weaker signals for the z-series
(complete analysis in SI Appendix, Table S2). By subtracting the
mass differences (ΔMW) for adjacent c-series (or z-series) ions,
the contributions of particular peptide NH atoms (or pairs of NH
atoms) can be obtained. Fig. 2D shows such a ΔΔMW analysis,
with the extracted H/D exchange of each peptide NH atom (or
pairs of NH atoms) at various times shown in open bars and the
fully exchanged mass difference shown in black bars. Corre-
sponding z-series data are shown in SI Appendix, Fig. S2A, with an
overall summary of both c-series and z-series data in SI Appendix,
Fig. S3. It is readily apparent that the V4 position is the most
strongly protected of all of the peptide NH, indicating that this
residue participates in the strongest H-bonding interaction. The
next strongest H-bonds emanate from the Y3 and N7 positions.
The V4 and Y3 positions ﬂank the P1 side-chain binding pocket.
Thus, it would be highly unlikely for the P1 side chain to sponta-
neously escape the P1 pocket, as recently proposed (9), and so we
sought other explanations for the key role of this region in DM-
mediated peptide exchange catalysis.
Substitution of αF54 Dramatically Increases Susceptibility of MHC II to
DM-Catalyzed Peptide Dissociation. To determine the relevance of
the region proximal to the P1 pocket for DM catalyzed peptide
dissociation, we engineered mutations in the extended strand re-
gion of the α-subunit at residues αF51, αS53, and αF54, and sur-
rounding the P1 pocket, at residues αL45, αF48, βF89, and βW153
(Fig. 3A, and SI Appendix, Fig. S4A and Table S3). As a control, we
alsomutated αQ57, located on the α-subunit helix one turn beyond
the extended strand region. We monitored the intrinsic rate of
peptide dissociation from the mutant proteins using Alexa488-la-
beled CLIP peptide in a ﬂuorescence polarization assay (Fig. 3 B–
G, blue triangles, and SI Appendix, Fig. S4 B–E). Dissociation time
courses ﬁt well to single exponential decays, with t1/2 and koff values
shown in SI Appendix, Table S1, ranging from a 9.5-fold increase in
dissociation rate for αF54C to a 1.9-fold decrease for αS53A.
We tested the susceptibility of the MHC II mutant proteins to
DM in a functional assay (Fig. 3 B–G and SI Appendix, Fig. S4 B–
E). In the range tested, peptide dissociation rate constants in-
creased linearly with increasing DM concentration for each of the
mutant proteins (Fig. 3H and SI Appendix, Fig. S5), with the slopes
reﬂecting the susceptibility of each mutant protein to DM-medi-
ated peptide dissociation. As previously observed in the context of
another MHC II protein (11), substitution of αF51 resulted in a
protein that was resistant to DM (Fig. 3E). The DM-susceptibility
of the control mutant αQ57C and P1 pocket mutants αL45A,
αF48A, βF89A, and βW153A were similar to WT, whereas αS53A
was approximately sevenfold more sensitive to DM than WT (Fig.





Fig. 1. HDx mass spectroscopy to evaluate MHC-peptide H-bonding
strengths. (A) Experimental design. Preformed complexes of HLA-DR1 and
inﬂuenza-derived HApeptide (MHC-HA)were transferred to a D2O-containing
solution, initiating exchange between macromolecular amide hydrogens and
solvent deuterons. At various times the reaction was quenched by transfer to
ice-cold pH 2.7 buffer, which removes the peptide from the MHC but mini-
mizes further HDx. (B) Mass spectra of free andMHC-bound HA peptide. (Left)
Isotopic distribution for the [M+2H]2+ ion of the unlabeled HA peptide.
(Center) HA peptide after equilibration in D2O. (Right) HA peptide eluted from
MHC-complex after 30-s incubation in D2O, showing MHC-mediated pro-
tection from HDx. (C) HDx kinetics, shown as average mass of the HA peptide
eluted fromMHC complex after various times of incubation in D2O. Wild-type
DR1, black symbols; F54C, red symbols. (D) Peptide dissociation kinetics, mea-
sured by a polarization assay using Alexa-488 labeled HA.
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αF54A were exquisitely sensitive to DM, with concentrations as
low as 30 nMDM, inducing large increases in peptide dissociation
rates (Fig. 3D andG). Values for the slopes of the DM-dependent
rate proﬁles (i.e., the DM susceptibility) were 302- and 378-times
greater for αF54C and αF54A, respectively, compared with WT
(Fig. 3H and SI Appendix, Table S3).
Previous studies have used the speciﬁc rate enhancement (i.e.,
the slope of the DM susceptibility curve divided by the intrinsic
dissociation rate constant) as a measure of DM’s catalytic efﬁcacy
toward a particular substrate (6, 15). Even after this normalization
the αF54 mutations still are extreme outliers, with speciﬁc rate
enhancement over 400 μM−1 for αF54A, almost 90-times greater
than for WT (Fig. 3I and SI Appendix, Table S3). The extreme
sensitivity of αF54C to DMwas not restricted to the CLIP peptide,
as it was also observed for theHApeptide (Fig. 3I, open bars, and J,
and SI Appendix, Fig. S6).
Substitution of αF54 Weakens MHC-Peptide H-Bonding Interactions.
Wedetermined the effect of the αF54Cmutation on the overall H-
bond network by HDx MS/MS. The amplitudes of the unresolved
initial HDx phases are the same for bothWT and αF54C (Fig. 1C).
The fast-phase amplitudes also are similar for WT and αF54C, as
are the respective half-lives for this phase (SI Appendix, Table S1).
However, the slow phase of HDx is signiﬁcantly faster for αF54C
than forWT, with half-lives of 1.8 and 18.1 h, respectively (Fig. 1C
and SI Appendix, Table S1). The pattern of deuterium in-
corporation observed by ETD/MS/MS is similar for αF54C as for
the WT-HA complex; however, the Y3, V4, and N7 NH exchange
faster than for the WT-HA complex (Fig. 2E and SI Appendix,
Figs. S2, S3, and S7). For the WT-HA complex, these H-bonds
represent the most stable of the interactions, and would be
expected to correspond to those most important in determining
the overall peptide-MHC lifetime. Our results suggest that the
αF54Cmutation disrupts these key H-bonds in the N-terminal half
of the peptide-binding groove.
Substitution of αF54 Dramatically Increases Binding to DM. To de-
termine whether the increased DM susceptibility observed upon
substitution of αF54 was associated with increased binding afﬁnity
for DM, we used a surface plasmon resonance binding assay.
Speciﬁc, saturable, dose-dependent binding was detected for both
αF54 variants but not for WT, αS53A, αF51A, or any of the other
mutants (Fig. 4 A–F and SI Appendix, Fig. S4 F–I). Equilibrium
binding analysis revealed Kd,app values of 0.5 μM and 0.7 μM for
αF54A and αF54C, respectively (Fig. 4G). We performed several
experiments to verify the speciﬁcity of the tight binding observed
for αF54A and αF54C to DM. First, we observed substantially
reduced binding ofDM to immobilized αF54C at pH 7.0 relative to
pH 5.6 (Fig. 4H), consistent with the known pH dependence of the
interaction (31). Second, binding was abrogated by preincubation
with a monoclonal antibody (LB3.1) speciﬁc for a conformational
epitope on MHC II (32) near the presumptive DM binding in-
terface (11) (SI Appendix, Fig. S8A). Finally, DM binding was
observed also for CLIP peptide complexes of αF54C but not WT
(SI Appendix, Fig. S8 B–D). These results indicate that αF54
substitutions, which increase sensitivity to DM-mediated peptide






Fig. 2. Mapping HDx at individual amide
groups using ETD mass spectrometry. (A)
Polypeptide fragmentation. Dashed lines and
opposing arrows represent different ion series
obtained upon backbone cleavage. (B) MHC
peptide-binding groove showing HA peptide
and MHC residues making conserved H-bonds.
(C) Representative data for HA c3 ion (Left)
and the c6 ion (Right) with no deuterium in-
corporation (H2O), with deuterium incorpo-
ration at various time points (2, 218, and 512
min) as bound to the MHC II, and for the fully
unprotected peptide (D2O). (D and E) Deute-
rium incorporation for individual amine
groups (ΔΔMW) along the HA peptide bound
to wild-type DR1 (D) or F54C (E) after different
times of incubation in D2O. Black bars, fully
exchanged fragment in D2O; open bars, HDx
for MHC-bound peptide after 2, 218, and
512 min in D2O.









Crystal Structure of αF54C-CLIP Shows a Conformational Change in
the Vicinity of a Critical DM Contact Residue. To investigate the
structural basis for the altered H-bond strengths, increased DM
susceptibility, and increased DM binding activity of αF54C, we
determined its 2.3 Å crystal structure in complex with the CLIP
peptide, and for comparison the 2.7 Å crystal structure of WT
bound to CLIP, in the same unit cell (SI Appendix, Table S4). Both
crystal structures have two molecules in the asymmetric unit. For
WT-CLIP structure, the molecules (blue and green in Fig. 5 and SI
Appendix, Fig. S9A–E) overlay with nomajor deviations (except for
an exposed loop near βP108 that shows large rmsd between most
MHC II structures solved to date). The structure of αF54C (purple
and red in Fig. 5 and SI Appendix, Fig. S9 A–E) overall was very
similar to WT except for a region proximal to the αF54C mutation
(indicated by carets in SI Appendix, Fig. S9 B andF), for which large
differences were observed speciﬁcally in one of the two molecules
in the asymmetric unit (SI Appendix, Fig. S9 F–I).
The conformational changes, which involve a loop between two
strands of the β-sheet platform, the short 310 helix encompassing
residues αL45 to αF50 at the edge of the binding site, and the
extended stand region αF51 to αF54, can be seen in Fig. 5. The
conformational change results in a ∼20° reorientation of the short
310 helix, together with a partial unwinding toward a more ca-
nonical α-helical pitch (compare Fig. 5 B and C). These changes
are accompanied by a concerted set of rotamer changes in residues
that surround the P1 pocket. Large changes are observed for αF48,
which positions its side chain on the side of the P1 pocket, dis-
placing βF89, which also undergoes a rotamer change, and for
αL45, which moves to contact βW153, replacing the contact nor-
mally made by the αF48 side chain. The rearrangements of αL45,
αF48, and βF89 resulted in changes in the shape and volume of the
P1 pocket (SI Appendix, Fig. S10).
The conformational changes in the 310 helix and adjacent strand
region appear to be induced by contact at the αF51 position in
molecule 2 of the asymmetric unit with another molecule in the
crystal (SI Appendix, Fig. S11). The contact is observed for both
WT and αF54C, but only in the mutant is the conformational
change induced. These changes result in lowered B-factors at the
contact site relative to the remainder of the α1β1 peptide-binding
domain, but increased B-factors for the bound peptide (SI Ap-
pendix, Fig. S12). The αF51 position is known to be a critical de-
terminant for DM binding and activity (11), and contact with
another molecule at the αF51 position may simulate the effect of a
contact at this position with DM.
Discussion
The mechanism of DM-mediated catalysis of peptide exchange on
MHC II proteins and the nature of the DM-MHC interaction has
been the subject of intensive investigation (6, 9–18, 24, 27). In this
work, we evaluated the contribution of MHC II structural ele-
ments at the N-terminal side of the peptide binding site, usingHDx
MS to measure MHC-peptide H-bonding strengths, site-speciﬁc
mutagenesis to identify MHC II side chains with important con-
tributions to DM binding and facilitated peptide exchange, and
crystal structure analysis of the HLA-DR1 mutant αF54C. Sub-
stitution of αF54 in the MHC II extended strand region of the
peptide binding site results in a protein with greatly increased
susceptibility to DM-mediated peptide release, increased DM-
binding afﬁnity, and increased MHC II-peptide dynamics, partic-
ularly in the MHC II-peptide H-bonding interactions that sur-
round the P1 pocket. The crystal structure of the αF54C reveals
conformational alterations near the N terminus of the bound
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Fig. 3. Substitution of αF54 results in a dramatic increase in the rate of DM
catalyzed peptide exchange. (A) Location ofmutated residues inMHCpeptide-
binding groove (additional mutations shown in SI Appendix, Fig S4). (B–G)
Peptide release kinetics in the presence of various concentrations of DM. (H)
The kobs values plotted against the concentration of DM. (Inset) Shows WT,
αQ57C, and αS53A with expanded y axis. (I) DM-mediated rate enhancements
were calculated for eachmutant by dividing the slope of the kobs vs. [DM] plots
by the intrinsic dissociation rates. Closed bars, MHC II-CLIP. Open bars, MHC II-




Fig. 4. Surface plasmon resonance analysis of αF54C/αF54A binding to DM.
(A–F) Various concentrations of DM were ﬂowed over immobilized WT and
mutant MHC II. (G) Equilibrium analysis of DM binding to immobilized αF54C
(circles) and αF54A (triangles), with Scatchard plot shown as an inset. (H and
I) pH Dependence, showing DM (10 μM) injected over immobilized αF54C (H)





















A B C 
Fig. 5. X-ray crystal structures ofWTand αF54C bound to the CLIP peptide. (A)
(Upper) Ribbon diagram of peptide binding groove with CLIP peptide in yel-
low. The peptideM91 side chainwhich occupies the P1 pocket is shown in dots.
(Lower) A 90° rotation showing end-on view. Boxes indicate regions expanded
in B and C. (B) (Upper) Overlay ofWTmol1 (blue),WTmol2 (purple), and αF54C
mA 90° rotation with additional residues αL45 and βW153. Dashed line rep-
resents helical axis. (C) αF54C mol2 (red) shown with the same alignment as
molecules in B.
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50) and changes in the ﬂanking extended strand regions (α39–44
and α51–54); adoption of the altered conformation is dependent
on contact of αF51, a known DM-MHC II contact site (11). The
extended strand region α51–54 is usually anchored by interaction
of the αF54 side chain with a hydrophobic cluster on the side of the
binding groove. Replacement of the αF54 side chain by cysteine or
alanine would weaken this interaction, and facilitate adoption of
an alternate conformation that favors DM binding.
Several factors indicate that the conformation observed in the
αF54C mutant can be adopted by the WT and is relevant to DM-
mediated peptide exchange. Modeling studies of MHC II suggest
that the N-terminal side of the peptide binding site undergoes
conformational alteration concurrent with peptide release (32–
34). In a molecular dynamics simulation of peptide-free MHC II
(32), we observed changes strikingly similar to those observed in
the αF54C structure determined here, in particular, a change in
pitch and partial unwinding of the 310 helix and concerted rotamer
changes of αF51,αF45, αF48 and βF89 (SI Appendix, Fig. S13). The
P1 pocket, a locus of conformational change in molecule 2 of the
αF54C crystal structure, is known as a key determinant ofMHC II-
peptide interaction (35) and has long been proposed by numerous
groups to be involved in DM catalyzed peptide exchange (9, 10, 13,
14, 25, 26, 36). Finally, the α39–44 strand, which also rearranges in
molecule 2 of the αF54C structure, carries two other residues in
addition to αF51 implicated in DM-MHC II contact: αE39, which
was identiﬁed in a random screen as a residue important in me-
diating DM’s functional effect (11); and αW43, which was identi-
ﬁed by mutagenesis as important in DM-DRbinding (9). Thus, the
altered conformation observed in the crystal structure of molecule
2 of αF54C provides a structural explanation for the involvement
of the regions previously implicated in DM-mediated catalysis.
A model for how the altered conformation observed for αF54C
might function as an intermediate state in the DM-mediated
peptide release pathway is shown in Fig. 6. In this model, in-
teraction of DM with the MHC II-peptide complex stabilizes a
conformation with decreased MHC-peptide H-bonding and rear-
rangements in the crucial P1 pocket (Fig. 6, red). These structural
alterations lead to reduced MHC II-peptide binding afﬁnity and
facilitated peptide release. DM interaction with this intermediate
form persists until binding by a peptide with afﬁnity sufﬁcient to
shift the equilibrium back toward the original MHC II-peptide
conformation with release of DM (Fig. 6, blue). If an exchange
peptide were not available, DM dissociation would lead to for-
mation of the peptide-refractive empty conformation (Fig. 6, or-
ange). Computational studies suggest that the conformation of the
peptide-free protein has alterations near the P1 pocket as well as
elsewhere in the binding groove (32–34), with the α-subunit ex-
tended stand region occupying part of the canonical peptide
binding site (32), creating a peptide refractive state. In the model
shown in Fig. 6, association with DM would reverse these inter-
actions, providing a structural explanation for DM’s chaperone
function. It is possible that the F54C mutation has stabilized the
peptide-receptive conformation by reducing the interaction of the
strand region with the P1 pocket, an interaction proposed to be
mediated by F54 engagement in the P1 pocket (32). Recently, a
model has been put forward for the DM-mediated peptide release
mechanism based on DM binding of HLA-DR2 variants, in which
spontaneous release of peptide from the P1 pocket facilitates DM
interaction (9). The hydrogen-deuterium experiments reported
here argue against such a model, because they demonstrate dis-
proportionate stability of theMHC-peptideH-bonds that ﬂank the
P1 pocket. The structure of the αF54C-CLIP complex reported
here, in which the P1 pocket is fully occupied, reveals a different
mechanism for facilitating DM interaction, through structural
changes in the 310 helix and adjacent strand regions.
A detailed molecular understanding of the DM-mediated pep-
tide-exchange mechanism has been elusive because of the lack of a
structural model that encompasses the dynamic interactions be-
tween DM and MHC II. The structures reported here describe a
unique characterization of conformational changes involved in
peptide exchange by DM, and provides a structural model for the
DM-receptive conformation of MHC II that is intermediate be-
tween a stable MHC II-peptide complex and the proposed pep-
tide-free conformation.
Materials and Methods
Protein Production. The extracellular domains of wild-type and mutant HLA-
DR1 α- and β-chains were individually expressed in Escherichia coli and fol-
ded in vitro as previously described (37). Soluble DM molecules secreted
from stably transfected Drosophila S2 cells were isolated by immunoafﬁnity
chromatography. HLA-DR1 and DM were further puriﬁed by size exclusion
chromatography before use (Superdex S200).
Polarization Assays. N-terminally acetylated HA (Ac-PKFVRQNTLRLAT-OH) and
CLIP (Ac-VSKMRMATPLLMQ-OH) peptides (21st Century Biochemicals) were
labeled with Alexa-488 tetraﬂuorophenyl ester (Molecular Probes) at position
K2 (HA) or K3 (CLIP). Peptide complexes were prepared by incubation ofWT or
mutant MHC II (150 nM) with 25-nM labeled peptide for 3 d at 37 °C in 96-well
low protein-binding black polystyrene assay plates (Corning) in 200 μL binding
buffer (100mMNa citrate, 50mMNaCl, 0.1%octyl glucoside, 5mMEDTA, and
1 mM PMSF). Intrinsic and DM-mediated dissociation was monitored in tripli-
cate by ﬂuorescence polarization (488-nm excitation, 520-nm emission) after
addition of 100-fold excess unlabeled HA peptide. Dissociation rate constants
were determined by ﬁtting to a single phase exponential decay. The rate en-
hancement by DM was calculated as the slope of the linear rate vs. DM con-
centration plot, and the DM-enhancement factor calculated as this slope
divided by the intrinsic (i.e., no DM) rate constant (6). Similar values were
obtained regardless of whether intrinsic dissociation rates were determined by
experiments performed in the absence of DM or by extrapolation of DM-de-
pendent rate proﬁles.
Surface Plasmon Resonance. Surface plasmon resonance experiments were
carried out on a Biacore 3000 instrument using CM5 chips and 10 mM sodium
citrate pH 5.5, 150mMNaCl, 3 mMEDTA, and 0.05% (vol/vol) surfactant P20 at
30 μL/min. Protein was immobilized by standard amine coupling using ethyl
(dimethylaminopropyl) carbodiimide and N-Hydroxysuccinimide. In the stan-
dard ligand coupling procedure, excess activated dextran carboxylate groups
are capped with ethanolamine. For surfaces capped this way we observed
signiﬁcant nonspeciﬁc binding of DM at pH 5.5, presumably because of
interactions with the carboxydextran matrix (pKa ∼5). Instead we capped with
a different reagent, 2-amino-ethyl-sulfate, which maintains a negative charge
at low pH, and observed low nonspeciﬁc binding at pH 5.5. Regeneration of
the DM-coupled surface was carried out by ﬂowing 50 mM CAPS pH 11.5 for
30 s until a stable baseline was reached. Binding interactions were ﬁt to a
heterologous binding model using BIAeval software.
Protein Crystallography. Crystals of αF54C CLIP complexes were grown at 4 °C
in hanging drops over 12% PEG 4000, 100 mM sodium acetate (pH 5.6), 100
mM ethylene glycol, 5 mM DTT. WT crystals were obtained under the same
conditions by streak seeding crushed F54C CLIP crystals. Crystals were
transferred to well buffer with 25% ethylene glycol before ﬂash freezing in
liquid nitrogen. Diffraction data collected under cryo conditions at the Na-
tional Synchrotron Light Source on the ×29 beamline (λ= 1.1 Å) from single
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Fig. 6. Model for DM interaction MHC II-peptide complex. Stable MHC II-
peptide complex conformation (blue), from crystal structures of MHC II-
peptide complexes. Arrow denoting motion of the αF51 and 310 helical re-
gion. DM receptive conformation (red), from Mol2 of the αF54C structure.
DM is shown surrounding the putative MHC II binding region at the N-ter-
minal side of the binding site. Peptide exchanges is facilitated in this form.
Peptide-free conformation (orange), from molecular dynamics simulation
model of the peptide-free MHC protein (32).









crystals (WT: 0.1 × 0.05 × 0.05, F54C: 0.6 × 0.07 × 0.07 mm) using an ADSC
Q315 detector were processed with HKL2000. Initial phasing was obtained
by molecular replacement using Phaser (38) with coordinates from another
HLA-DR1 structure (PDB code: 1PWY) as a search model. Multiple rounds of
reﬁnement and building were carried out using Phenix (39) and COOT (40).
PDB ID codes are 3QXD (F54C-CLIP) and 3QXA (WT-CLIP).
H/D Exchange. WT and αF54C loaded with HA peptide were transferred to PBS
pH 7.2 and concentrated to 55 μM. To initiate H/D exchange, MHC II-peptide
complexes or HA peptide alone were diluted 1:10 into PBS in D2O, followed by
incubation at 25 °C. At each time interval we quenched the reaction by diluting
the exchangemixture 1:10 into 1 M glycine pH 2.7 at 4 °C and ﬂash-freezing at
−40 °C. All components of the LCMS instrument (Thermo Scientiﬁc) in contact
with the sample were chilled to 4 °C before data collection. Samples were di-
luted twofold in ice cold buffer A (0.1% TFA in 2% ACN) immediately before
injection (50 μL/min) onto 1 × 15-mm C4 PepMap300 and C18 PepMap100
columns (Dionex) connected in series. With transfer to 25% ACN the MHC II is
retained and the peptide is released for infusion into the mass spectrometer,
using capillary temperature 275 °C and source voltage 4.5 kV. Spectra were
acquired fromm/z 450–1,600with a cycle time of∼1 s. Averagem/z valueswere
calculated by summing each peak in the isotope distribution weighted by its
relative abundance, and converted to fractional H/D exchange by reference to
the value for unexchanged free peptide in the same experiment. Fractional H/D
exchange versus time curves were ﬁt to a two-phase exponential equation.
The expected isotope distribution for HA peptide was calculated from the
atomic formula (C69H119N18O19). For calculation of the expected mass distri-
bution under various conditions, the probability of H/D exchange at each of
the 12 peptide main chain amide hydrogens was estimated using a binomial
equation, which assumes equal probability of exchange at each position:
PðkÞ ¼ n!=ðk!ðn− kÞ!Þ pk ð1−pÞðn− kÞ
where n = 12 for the 12 amide positions, p = 0.9 for exchange into 90% D2O,
and k is number of hydrogens exchanged.
Electron Transfer-Induced Dissociation MS. Peptides eluted as described above
were introduced into an amaZon-ETD quadropole ion-trap instrument
(Bruker Daltonics) operating in positive ion mode and subjected to ETD
fragmentation. ETD spectra were processed and assigned to c- and z-series
ions using Bruker Daltonics Data Analysis and BioTools software. Average
peptide fragment masses observed at various times in D2O were compared
with H2O values to determine HDx ΔMW. Sequential c-series or z-series ions
were subtracted to give ΔΔMW values, which represent the amount of
deuterium incorporation per amide (or pairs of amides) at each time point.
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